Anybody else out there interested in these?

2002 Results are due in April, and they are expected to show a maiden profit.
Last week I opened a small speculative long (spreadbet), but I am looking to add to this position a lot more if we get any sort of resolution over Iraq crisis before the results which should spark a broad market rally from which SKP could really benefit and have a strong run-up.

DYOR etc.


Here is a recent research note from Merrill Lynch (they estimate 0.25p EPS for 2002):


Merrill Lynch FlashNote

7 February 2003

SkyePharma

Newsflow Set To Continue BUY

Reason for Report: Company Update

EPS (Dec): 2001A -1.19p; 2002E 0.25p; 2003E 2.13p
P/E (Dec): 2001A NM; 2002E 180.0x; 2003E 21.1x

Michael Ashton, CEO SkyePharma, gave an upbeat and informative presentation today.

Depomorphine appears on track for US submission in June 03. The two pivotal trials (hip and lower abdominal surgery) have been concluded. To date, the results appear encouraging. Management believe that safety (eg respiratory depression and nausea) is not an issue for the drug.The company is also conducting an additional trial in C section patients which is completing enrollment and should be included in the European submission for Depomorphine later this year. We expect the pivotal trial data for Depomorphine to be presented at the American Society of Clinical Anaesthesiologists in October 2003.

Paxil CR continues to grow (accounting for c.26% of total Paxil scrips in the US). 50% of these Paxil CR scrips are repeat and Paxil CR accounts for c.7% of the total SSRI antidepressant market in the US. Paxil CR is already filed for pre-menstrual dysphoria disorder (PMDD). However, GSK also plans to submit the intermittent treatment of PMDD later this year.

SKP also confirmed that Quintiles plans to present new data for Solaraze at the American Society of Dermatology in March. SKP believes that Solaraze is making in-roads into the actinic keratosis market and appears to be taking market share from Ephedrex (5-FU). Clinical trials in Australia are on track, with SKP planning to submit Solaraze to the Australian regulatory authorities in 2004 (second largest market opportunity after the US).

Enzon has already started to market DepoCyt in the US and SKP expects to see wider usage of the drug by key oncologists in the next few months. Phase IV studies for the neoplastic meningitis indication are on track, with an FDA Advisory Committee meeting (ODAC) scheduled next month.

Overall, we expect the newsflow for SKP to continue and reiterate our BUY recommendation with a price objective of 80p (based on applying the speciality pharma multiple to our 06E EPS of 14p and discounting back agressively at 30% p.a.). Risks to the stock include the general risk of drug development delay and product approval failure.

You seem to be losing your case robstuff - gradual rises with no particularly recent RNS is the way I like to see things going

Interesting that Ashton was supposed to be doing the SG Cowan presentation but it is now being done by Peter Laing as Ashton has been detained in London for an important meeting - something or nothing?

Presentation is live on the website

A notorious Pump and Dump poster on Advfn is giving a short term boost that's all, expect 28 by Xmas. Switch to Oxb which is now looking bonkers undervalued.

Robstuff

If you believe Ravens thread moves share prices then you really are delusional

And as for one of your earlier posts:

robstuff - 09 Nov 2005 22:14 - 164 of 167
Dump it, downward trend will continue..

Does this not apply to OXB because that one sharp knife youre tring to catch

With the CEO being called back in to the office at the last minute, makes me wonder have Skyepharma received a bid. This meeting has been planned well in advance with the slides geared towards Michael Ashton. The company could have said he has been taken ill, but instead quote important meeting. Therefore I would not rule out a bid for the company, this would involve the major share holders and top directors being called ahead of press speculation. This is an emergency meeting and one doubts very little this has anything to do with the pulmonary D3 package. One would not be surprised to read an RNS later today or tomorrow.

As always do your own research before buying or selling shares.

SkyePharma PLC ("the Company")
Notification of Major Interest in Shares


In accordance with the Companies Act 1985 (as amended) the Company was informed
on 9 November 2005 that following the disposal of an interest in shares, the
majority of which were held for stock borrowing and lending activity, Morgan
Stanley Securities Limited ("MSSL") no longer held a notifiable interest in the
Company. MSSL is a member of the Morgan Stanley group of companies.

------

The funds on loan are being called in. This is very positive.

Is it boom time yet ?

Going well early doors.

Yes indeed.

Some large placements pre-market. Looks very attractive at the moment, good volume in a pleasant up trend, The weekend media could read interesting news regarding Skyepharma. There does not appear much resistance up to 50p once 44p has been broken. Let the trend be your companion.

As always please do your own research.

48,soon with a bit of luck,happy days.

What a day to be on these drugs !

Dave, may be needing some more of them this morning:

Skyepharma PLC
14 November 2005



FOR IMMEDIATE RELEASE 14 November 2005

SkyePharma PLC

Strategic Review

LONDON, ENGLAND, 14 November, 2005 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP)
announces that following a recent unsolicited approach from a third party, the
Board of SkyePharma has decided to review all of its strategic options,
including inter alia offers for the company as a whole.

The Board has appointed Lehman Brothers as sole financial adviser to undertake
this review. There is no certainty that the review will result in any change to
the present ownership structure of the company. A further announcement will be
made when appropriate.

For further information please contact:

SkyePharma PLC +44 207 491 1777
Peter Laing, Director of Corporate Communications +44 7766 906626
Sandra Haughton, US Investor Relations +1 212 753 5780

Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court/ Rebecca Skye Dietrich

Top Gun Trader, you are a very smart observer. That was spot on, very astute.
I wonder who it could be though, anyway. happy trading

Fingers crossed for blue,,bloomberg,,yes.

Who said 50 !!

Nice little profit that in & out in a few weeks result.

Good Morning.

Any bid for the company would have to be in the region of 65p with assets and pipeline products. Skyepharma now have the upper hand with Flutiform which places them in a very strong negotiating position, one is very surprised to see Skyepharma trading around 50p today; no doubt this will change and move forward through out this week. It has been rumoured that Merk and Pfizer are both interested in SKPs pipeline, but no doubt we will see other big names now appear on the scene Glaxo being one of them no doubt.

Please do your own research.

This is like 0.75p in old money.

Unbelievable mis-management...look at the sp fall like it's on a skydiving TV prog.
Grief it looks bad, very bad. ... 28.5pence.
(Execs should be paid 28p in the pound, at least they'd feel some pain.)

Psst if management is awake, still - get on with something to make some Money.

Oh deary, a Director buys a few hundred shares - wowie - that's a strong signal that things are very wrong still . . . . what exactly are they doing, I wonder? This is years after their original claims to be cutting edge and shareholter return-focus.
- Humm